Page 1

Press Release Inside / regulated information IBA BUSINESS UPDATE - THIRD QUARTER 2021 lba Louvain - La - Neuve , Belgium , November 18 , 2021 - IBA ( Ion Beam Applications S.A. , EURONEXT ) , the world leader in particle accelerator technology , today announces its business update for the third quarter ending 30 September 2021 . Group Overview Strong performance across all business lines Ongoing commitment to stakeholder approach , delivering the best offering to our customers and investing for long - term sustainable growth whilst meeting ESG targets Strong balance sheet maintained , with EUR 91 million unaudited net cash ( 30 June 2021 : EUR 69 million ) Olivier Legrain , Chief Executive Officer of IBA commented : " IBA has continued to perform strongly in the second half of 2021 with solid progress across all business units . We have a highly active pipeline of new opportunities and are particularly excited about the marked revival in proton therapy activity in the important US market . Our Other Accelerators and Dosimetry businesses have also been exceptionally strong in the second half of the year with encouraging momentum as we approach 2022 . " A core component of our roadmap towards sustainable growth is investment in future innovation to deliver strategic impact . In this regard , we were pleased to provide updates on a range of initiatives at the recent ASTRO conference , as well as several strategic partnerships , including in the promising field of radiotherapeutics . We are very excited about future prospects across our business lines and are in a confident position to achieve long - term profitability , with our stakeholder approach underpinning all of our business activities . " Business Unit Highlights ( including post - period end ) Proton Therapy 13 ProteusⓇONE¹ and 8 Proteus PLUS¹ projects currently ongoing . Strong pipeline of new global opportunities with significant activity in the US and Asia Contract signed for a five room Proteus®PLUS System in China including a multi - year service contract Post - period end , finalized contract with Advocate Radiation Oncology in Florida , which previously selected IBA's ProteusⓇONE for its new Radiation Oncology Centre , including a multi - year service contract Post - period end , announced updates at ASTRO , including expansion of strategic partnership with RaySearch within Flash and proton ARC therapy projects , and the launch of Campus , the world's first online proton therapy platform 1 * ProteusⓇONE and ProteusⓇPLUS are brand names of Proteus 235 Press release | November 18 , 2021 1 Certified IBA Ion Beam Applications SA B Corporation Chemin du Cyclotron , 3 | 1348 Louvain - la - Neuve | Belgium | RPM Brabant - wallon VAT : 0428.750.985 | T +32 10 47 58 11 | F +32 10 47 58 10 info@iba-group.com | iba-worldwide.com Life , Science .